Biotechnology
Samsung Biologics' $1.81 billion bid for Swiss peptide manufacturer PolyPeptide Group is not just an M&A story. It is a strategic play for control of the GLP-1 drug supply chain, and a signal of where the CDMO industry is heading.
Pharmaceuticals
Merck's enlicitide becomes the first oral PCSK9 inhibitor approved by the FDA, potentially transforming cholesterol treatment by eliminating the need for injections.
Biotechnology
Ipsen's $1.75 billion acquisition of Kartos Therapeutics brings navtemadlin, a novel MDM2 inhibitor, to myelofibrosis patients who have failed ruxolitinib. The drug targets a complementary pathway with promising Phase 1b/2 data showing disease modification signals.
Pharmaceuticals
AbbVie's $10.9 billion acquisition of Apogee Therapeutics signals a strategic shift in immunology drug development. The deal centers on zumilokibart, a long-acting IL-13 inhibitor designed to compete with Dupixent through superior dosing convenience.
Biotechnology
Parabilis Medicines raised $670 million in the largest-ever venture-backed biotech IPO, breaking Moderna's eight-year record. We examine what the company's novel Helicon peptide platform and the market's appetite for it reveal about where drug discovery is heading.
Biotechnology
GSK's $10.6 billion acquisition of Nuvalent Bio secures two near-approval precision oncology drugs for NSCLC and signals a broader strategic shift toward building a lung cancer franchise. We examine what the deal reveals about where targeted therapy is heading.
Biotechnology
Johnson and Johnson's $1 billion acquisition of Firefly Bio signals a major shift in cancer drug design. We explore what degrader antibody conjugates mean for the future of oncology and why this bet matters for patients with KRAS-driven cancers.
Pharmaceuticals
Data from Boehringer Ingelheim's survodutide Phase 3 trials reveals a mechanistically distinct approach to obesity treatment, with exceptional reductions in visceral and liver fat that reframe what obesity drugs can achieve.
Policy
When Eli Lilly announced it was cutting its planned German investment in half, the news landed with the weight of a verdict. Together with Boehringer Ingelheim's cancellation of 900 million euros in spending, more than $2 billion in future investment was pulled from Germany in a single day.
Pharmaceuticals
Pfizer's $10.5 billion deal with China's Innovent Biologics signals a major strategic shift in how Western pharma is leveraging Chinese biotech innovation in oncology.
Biotechnology
Eli Lilly is making a $4 billion commitment to rebuild its infectious disease portfolio from scratch, acquiring three vaccine developers and signaling a strategic pivot away from its GLP-1 dominance.
Biotechnology
Roche's $1.05 billion acquisition of PathAI signals that AI-powered digital pathology is becoming as strategically important as drug development itself in precision oncology.